IDEATE IPILIMUMAB DRUG EVALUATION IMMUNOTHERAPY IN SQUAMOUS NSCLC Logo (USPTO, 04/12/2012)
USPTOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The US trademark IDEATE IPILIMUMAB DRUG EVALUATION IMMUNOTHERAPY IN SQUAMOUS NSCLC was filed as Word and figurative mark on 04/12/2012 at the U.S. Patent and Trademark Office.
It was registered as a trademark on 02/18/2014.
The current status of the mark is "CANCELLED - SECTION 8".
Logodesign (Wiener Klassifikation)
#USPTO: 03.23.15 - Sperm cells, Micro-organisms, Amoebas #USPTO: 26.01.29 - Helixes, DNA helix #Set of lines evoking speed or propulsion #Other lines or bands #USPTO: 26.11.26 - Oblongs as carriers for words, letters or designs
| Trademark form | Word and figurative mark |
| File reference | 4485747 |
| Register number | 85595704 |
| Application date | April 12, 2012 |
| Entry date | February 18, 2014 |
| Expiration date | February 18, 2024 |
Trademark owner
430 E. 29th Street, 14th Floor
10016 New York
US
10016 New York
US
Trademark representatives
P.o. Box 4000
08648-4000 Princeton
US
goods and services
42
Scientific and computer services
ID: 13